IL6 and obesity disorder: Since immunotherapy targeting T cells normalizes glucose homeostasis9, and as T cell inhibitors reduce CD8+ T cells and proinflammatory macrophages in visceral adipose tissue25, we investigated whether abrogating IL-6 signalling in T cells would affect the development of obesity-associated tissue inflammation and, subsequently, alter systemic glucose homeostasis.